SCHEMBL16608347

SCHEMBL16608347

C=C/C=C(/Cl)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20094640 0.78
SCHEMBL18945725 0.74 ALDH1A1 (0.33)
SCHEMBL10724304 0.71 TSHR (0.46)
SCHEMBL8340385 0.71
SCHEMBL24664861 0.70
SCHEMBL11437735 0.69
SCHEMBL1067519 0.69
SCHEMBL8925658 0.69
SCHEMBL11437737 0.69
SCHEMBL20462363 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023102239-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed
WO-2023102529-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed
WO-2023086800-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2023-05-19 WO disclosed
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2023-05-04 US disclosed
US-20230011968-A1 TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-01-12 US disclosed
WO-2023277824-A2 DIVERSE FUNCTIONALIZATION OF HYDROSILANES AND PROGRAMMABLE SYNTHESIS OF MULTISUBSTITUTED ORGANOSILANES ENABLED BY NEUTRAL EOSIN Y PHOTOCATALYSIS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-01-05 WO disclosed
US-20220388997-A1 COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF GANNEX PHARMA CO., LTD. (CN) 2022-12-08 US disclosed
WO-2022147448-A1 COMPOUNDS AND METHODS FOR MODULATING FXR TERNS PHARMACEUTICALS, INC. (US) 2022-07-07 WO disclosed
US-11198703-B2 Process for the preparation of SGLT2 inhibitors and intermediates thereof Piramal Enterprises Limited (IN) 2021-12-14 US disclosed
EP-3504205-B1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX INC (US) 2021-08-04 EP disclosed
WO-2020185606-A1 MACROCYCLIC COMPOUNDS ZENO MANAGEMENT, INC. (US) 2020-09-17 WO disclosed
US-20200123186-A1 A PROCESS FOR THE PREPARATION OF SGLT2 INHIBITORS AND INTERMEDIATES THEREOF Piramal Enterprises Limited (IN) 2020-04-23 US disclosed
US-20190233420-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. 2019-08-01 US disclosed
EP-3456713-A1 PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES Japan Tobacco Inc. (JP) 2019-03-20 EP disclosed
US-10206912-B2 Heteroaryl sulfonamides and CCR2/CCR9 CHEMOCENTRYX, INC. (US) 2019-02-19 US disclosed
WO-2017118294-A1 FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF 广州市恒诺康医药科技有限公司 2017-07-13 WO disclosed
EP-3187492-A1 PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY The University of Tokyo (JP) 2017-07-05 EP disclosed
US-20170095458-A1 HETEROARYL SULFONAMIDES AND CCR2/CCR9 CHEMOCENTRYX, INC. (US) 2017-04-06 US disclosed
EP-1933622-B1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF SECOND GENOME INC (US) 2016-03-09 EP disclosed
WO-2015048311-A1 NOVEL FUNCTIONALIZED 5-(PHENOXYMETHYL)-1,3-DIOXANE ANALOGS EXHIBITNG CYTOCHROME P450 INHIBITION CORTENDO AB (PUBL) (US) 2015-04-02 WO disclosed